Spyre Earnings Reports

Spyre Therapeutics, Inc. reported a net loss of $44.773 million for the three months ended March 31, 2025, compared to a net loss of $43.857 million for the same period in 2024. The increase in net loss was primarily driven by higher research and development expenses, partially offset by an increase in interest income and a decrease in the fair value of CVR liability.

Spyre Therapeutics reported no revenue for Q4 2024, with a net loss of $56.3 million. The company ended the quarter with $603.1 million in cash, cash equivalents, and marketable securities, extending its cash runway into the second half of 2028. Key developments included positive interim Phase 1 data for SPY001 and expansion of SPY002 into rheumatoid arthritis.

Spyre Therapeutics reported a net loss of $69.0 million for the third quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $414.2 million as of September 30, 2024, expected to fund operations well into 2027.

Spyre Therapeutics reported a net loss of $38.8 million for the second quarter of 2024. The company's cash and cash equivalents, marketable securities, and restricted cash totaled $426.3 million as of June 30, 2024. Dosing was initiated in the Phase 1 trial of SPY001, with interim proof-of-concept data expected by year-end 2024.

Spyre Therapeutics reported a net loss of $43.9 million for the first quarter of 2024. The company's cash position was $485.0 million as of March 31, 2024, providing a cash runway well into 2027. SPY001 is on track to begin first-in-human studies in the second quarter of 2024 and SPY002 remains on track to begin first-in-human studies in the second half of 2024.

Spyre Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting the advancement of its IBD therapies and a strong cash position of $339.6 million. The company is progressing with clinical studies across multiple programs and anticipates Phase 2 evaluation of rational therapeutic combinations in IBD patients in 2025.

Aeglea BioTherapeutics reported a net loss of $40.1 million for the third quarter of 2023, with R&D expenses totaling $24.7 million and G&A expenses totaling $8.6 million. The company's cash and cash equivalents, marketable securities, and restricted cash totaled $204.9 million as of September 30, 2023.

Aeglea BioTherapeutics reported second quarter 2023 financial results, including $236.7 million in cash and cash equivalents, $0.7 million in revenue, and a net loss of $217.1 million. The company completed the acquisition of Spyre Therapeutics, raised $210.0 million in gross proceeds, and sold global rights to pegzilarginase for $15.0 million upfront and up to $100.0 million in contingent milestone payments.

Aeglea BioTherapeutics reported a net loss of $18.4 million and revenue of $0.2 million for the first quarter of 2023. The company had $39.8 million in cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023.

Aeglea BioTherapeutics reported Q4 2022 financial results, including development fee revenues of $0.2 million and a net loss of $18.8 million. The company's cash, cash equivalents, marketable securities, and restricted cash totaled $57.3 million as of December 31, 2022, expected to fund operations into Q4 2023.

Aeglea BioTherapeutics reported $75.2 million in cash as of September 30, 2022. The company recognized development fee revenues of $0.2 million in the third quarter of 2022. Research and development expenses totaled $12.0 million and general and administrative expenses totaled $7.0 million for the third quarter of 2022. Net loss totaled $18.2 million for the third quarter of 2022.